New Roche Data to be Presented at ASCO Offers Further Hope for Cance... (ecifically designed to target and ...)

HOME >> MEDICINE >> TECHNOLOGY

New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients

Date:5/15/2008

ecifically designed to target and

block the function of HER2, which causes fast growing, aggressive

breast cancer tumours. Herceptin delivers high cure rates for women

with HER2 positive early breast cancer and extends survival across all

stages of HER2 positive breast cancer by activating the immune system

and suppressing HER2. Herceptin is considered the foundation of care in

women with HER2-positive breast cancer and is recommended in treatment

guidelines throughout the world.

-- Colorectal cancer is the most common cancer in developed countries(4)

and the second most common cause of death from cancer across all cancer

types in men and women across Europe.(5)

-- Avastin acts by blocking VEGF, the key mediator of tumor angiogenesis,

offering patients a better chance of significantly improved survival.

Avastin is the first anti-angiogenic inhibitor to increase survival in

first and second line treatment and to provide significant improvements

in the time that patients can live without their disease advancing.

The 2008 ASCO Annual Meeting takes place from May 31 to June 3, McCormick Place, Chicago, Illinois, USA. Full details can be found at http://www.asco.org .

If you or your media colleagues are interested in attending the Roche Media Event during ASCO on 30th May, where the data outlined in brief above will be presented, please contact Anne Cameron (see details below).

References:

1. Wilking N and Jonsson B. A Pan-European comparison regarding patient

access to cancer drugs. Karolinska Institute in collaboration with

Stockholm School of Economics, Stockholm, Sweden, 2005

2. World Health Organisation (WHO) 2003.

http://www.who.int/mediacentre/releases/20
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile

Post Your Comments:

New Roche Data to be Presented at ASCO Offers Further Hope for Cance...(ecifically designed to target and ...),Health